[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @PGainz96934 Pasha Gainz Pasha Gainz posts on X about $alt, $vktx, alt, ceo the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1799095376638615552/interactions)  - X Week XXXXXX +25% - X Month XXXXXX -XX% - X Months XXXXXXXXX -XX% ### Mentions: X [#](/creator/twitter::1799095376638615552/posts_active)  - X Week XX -XX% - X Month XXX +8% - X Months XXX +864% ### Followers: XXX [#](/creator/twitter::1799095376638615552/followers)  - X Week XXX +3.40% - X Month XXX +17% - X Months XXX +163% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1799095376638615552/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXX% [finance](/list/finance) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [$alt](/topic/$alt) #2, [$vktx](/topic/$vktx) 13.73%, [alt](/topic/alt) #421, [ceo](/topic/ceo) 7.84%, [$mdgl](/topic/$mdgl) 3.92%, [$nvo](/topic/$nvo) 3.92%, [$vik](/topic/$vik) 3.92%, [$1020b](/topic/$1020b) 1.96%, [$gocr](/topic/$gocr) 1.96%, [events](/topic/events) XXXX% **Top accounts mentioned or mentioned by** [@pharmdca](/creator/undefined) [@meadowcapital](/creator/undefined) [@keylimepieco](/creator/undefined) [@randall21161948](/creator/undefined) [@fat_pockets123](/creator/undefined) [@meangenebio](/creator/undefined) [@brwtoovey](/creator/undefined) [@xairsman](/creator/undefined) [@doctorsalomon](/creator/undefined) [@justpavankumar](/creator/undefined) [@alt_nicholson](/creator/undefined) [@fluffer9](/creator/undefined) [@vtcarguy81](/creator/undefined) [@pacha8x](/creator/undefined) [@noureddinmd](/creator/undefined) [@aditharun](/creator/undefined) [@sanctuarybio](/creator/undefined) [@hatedmoats](/creator/undefined) [@yaireinhorn](/creator/undefined) [@timopler](/creator/undefined) **Top assets mentioned** [AltLayer (ALT)](/topic/$alt) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Novo-Nordisk (NVO)](/topic/$nvo) [Viking Holdings Ltd (VIK)](/topic/$vik) [Advanced Micro Devices (AMD)](/topic/$amd) [Amgen, Inc. (AMGN)](/topic/$amgn) [Sanofi (SNY)](/topic/sanofi) ### Top Social Posts Top posts by engagements in the last XX hours "If Evercore is really signaling $1020B takeouts coming in obesity/metabolic theres only one name that actually fits that profile: $ALT Altimmune. Why Because Pemvidutide isnt another GLP-1 copy. Its the only late-stage asset that hits every strategic gap Big Pharma cares about right now: True MASH efficacy + fibrosis improvement Best-in-class lean mass preservation Cleaner tolerability without the brutal nausea curves A GLP-1/GC balance that covers obesity metabolic disease and liver disease in one shot Pipeline in a drug; Obesity MASH AUD ALD and potentially oral Thats not incremental thats" [X Link](https://x.com/PGainz96934/status/1996667665541484848) 2025-12-04T19:47Z XXX followers, 1057 engagements "Todays move in $GOCR is actually a small but very real catalyst for $ALT. It reinforces how sensitive the market is to any credible oral obesity signal. What matters is the takeaway: convenience and adherence are being rewarded immediately by the market and thats where $ALT could ultimately stand out even more. Pemvidutides profile points to better tolerability and adherence which are the exact pain points holding current orals back. So while $GPCR news isnt about $ALT directly its an obvious sentiment mover. It sets the setup. If and when ALTs oral data or clarity hits the re-rate should be" [X Link](https://x.com/PGainz96934/status/1998040946152190259) 2025-12-08T14:44Z XXX followers, XXX engagements "Youre absolutely right about patience but the comparison to $MDGL doesnt hold when you look under the hood because $VKTX is dealing with issues Madrigal never had and $ALT Pemvi is the one with the true clean shot at upside. Heres the reality: X Vikings safety & tolerability problems are not normal volatility theyre structural. Madrigal never had: Severe GI events in 44%+ of patients Double-digit discontinuation rates Dose-limiting tolerability even in Phase X But Viking does. That means shrinking eligible patient populations and real commercial limitations. Price volatility is one thing" [X Link](https://x.com/PGainz96934/status/1993382803568787825) 2025-11-25T18:14Z XXX followers, XXX engagements "@QualityInvest5 Buy $ALT and worry less" [X Link](https://x.com/PGainz96934/status/1993788477830517207) 2025-11-26T21:06Z XXX followers, XXX engagements "I havent posted in a couple days so heres your Pemvi refresher. While everyone argues about nonsense the only drug in this space that actually checks every box for MASH + obesity is $ALT Pemvidutide (Pemvi). A quick reset: 🚀 Efficacy: Top-tier weight loss without extreme or unsafe dosing Best liver fat reduction outside of a THR drug (competitive even with them) Dramatic CASED improvements and full metabolic cleanup Durability nobody in the incretin crowd has matched 🛡 Safety the real separator: No retatrutide-style GI chaos No $VKTX-style tolerability blowups Discontinuations are" [X Link](https://x.com/PGainz96934/status/1994110615351177319) 2025-11-27T18:26Z XXX followers, XXX engagements "@Ashton_1nvests $ALT and $AMD" [X Link](https://x.com/PGainz96934/status/1994110737481109563) 2025-11-27T18:27Z XXX followers, XXX engagements "Not really and heres why. $AMGN Efinopegdutide looks interesting on paper but it still sits in the same class of high-potency incretin stacks that consistently run into the exact problems $ALT Pemvi avoids: GI toxicity scales with potency and efinopegdutides profile already shows the same nausea/vomiting patterns you see with other GLP-1 heavy drugs. Durability is unknown early signals show strong initial drops but no clarity on long-term flattening metabolic stability or real-world tolerability. No liver-first mechanism Pemvi has direct hepatic action (GCGR) that drives MASH improvement in a" [X Link](https://x.com/PGainz96934/status/1994124166979821897) 2025-11-27T19:20Z XXX followers, XXX engagements "@mvcinvesting Buy $ALT and relax" [X Link](https://x.com/PGainz96934/status/1994158969045033000) 2025-11-27T21:38Z XXX followers, XXX engagements "@TacticzH EPS will fall off the patent plateau thats why its sold off and will continue to do so unless they make a pipeline changing acquisition such as acquiring $ALT" [X Link](https://x.com/PGainz96934/status/1994440353093472287) 2025-11-28T16:16Z XXX followers, XXX engagements "🔥 One of the most underrated aspects of $ALT The exec team. Everyone debates data but leadership is another place where Altimmune separates itself from the entire sector. X Vipin Garg PhD CEO Hes the one who acquired pemvidutide early because he saw what others didnt. And he leaned into MASH years before Big Pharma caught on. Vision + conviction. Thats why ALT is ahead of the curve. X Christophe Arbet-Engels MD PhD CMO 30+ years in global pharma running late-stage metabolic/liver programs. Exactly the profile you want entering Phase X MASH. X Linda Richardson CCO Just brought in for" [X Link](https://x.com/PGainz96934/status/1994445371704025457) 2025-11-28T16:36Z XXX followers, 2163 engagements "Youre lumping drugs together that arent even in the same universe mechanistically or clinically. Already have dual agonists is a perfect example of not understanding the differences between combos vs balance. $ALT Pemvidutide isnt just another dual agonist. Its the ONLY GLP-1/glucagon program with: ✅ Clinically validated high-fat mass loss with industry-best lean preservation Survodutide and Mazdutide both cut lean mass as badly as tirzepatide 2540% of total loss. Pemvi is sitting at XX% lean beating the GLP-1 class and avoiding the glucagon penalty. Thats why HCPs keep calling it the" [X Link](https://x.com/PGainz96934/status/1994803049412403472) 2025-11-29T16:18Z XXX followers, XXX engagements "Im glad it worked well for you genuinely. But your personal response doesnt erase the clinical reality seen across hundreds of patients. Individual anecdotes population-level safety. 🔹 Retatrutides real safety profile (from the actual data): 4050% of patients experienced moderatesevere GI AEs Discontinuation rates were XX higher than pemvidutide Significant HR and BP elevations CK elevations gallbladder events pancreatitis signals Lipid rebound when dose escalates Lean mass loss 3040% of total weight loss Dose ceilings because tolerability breaks before efficacy does None of that goes away" [X Link](https://x.com/PGainz96934/status/1994856540126523555) 2025-11-29T19:50Z XXX followers, XXX engagements "@brwtoovey @BowTiedBiotech What you meant to say is that you cant comprehend what Im saying therefore it hurt your head there I fixed it for you smooth brain. Your $VKTX position is in serious trouble no joke" [X Link](https://x.com/PGainz96934/status/1994947324477673507) 2025-11-30T01:51Z XXX followers, XX engagements "📌 In catalyst-driven names price action is the last thing that matters. For companies like $ALT real value comes from: Strong fundamentals Clinical data and execution A fortified balance sheet Major catalysts ahead (48-week readout FDA EOP2 Phase X design oral Pemvi) Strategic positioning + clear big-pharma interest Thats what rewrites valuations not daily candles. And while people argued over noise the chart quietly started showing accumulation higher lows and a clean uptrend exactly what you see before a catalyst cycle kicks in. This is why you focus on the setup not the swings. When the" [X Link](https://x.com/PGainz96934/status/1994950526409015635) 2025-11-30T02:04Z XXX followers, XXX engagements "@Mr_Derivatives Yup. Thinking about the millz to be made in $ALT and not even exaggerating" [X Link](https://x.com/PGainz96934/status/1994974590280618078) 2025-11-30T03:39Z XXX followers, XX engagements "$ALT just made a meaningful leadership shift with Durso stepping in as Garg exits at month-end and the timing is everything. In my opinion this isnt routine; its a strategic repositioning ahead of the most important stretch in the companys lifecycle. With the 48-week MASH biopsy readout approaching the upcoming FDA end-of-Phase-2 meeting and the window for a partnership or strategic transaction bringing in Durso now signals a push for tighter execution stronger communication and clearer alignment. Gargs departure removes a layer investors have questioned recently and gives Durso clean runway" [X Link](https://x.com/PGainz96934/status/1995592425763422386) 2025-12-01T20:34Z XXX followers, XXX engagements "Durso taking over as CEO is a much bigger signal than people think. This isnt just another management reshuffle in my opinion. This finalizes a leadership realignment that has been quietly building for more than a year. Altimmunes $ALT top leadership now shares an unusually deep commercial and clinical background in metabolic and liver disease and a striking amount of it traces back to Sanofi $SNY. Jerry Durso spent more than XX years at $SNY in senior U.S. and global commercial roles especially in diabetes and metabolic disease before leading Intercept. Linda Richardson the new CCO also came" [X Link](https://x.com/PGainz96934/status/1995623416649351179) 2025-12-01T22:37Z XXX followers, XXX engagements "@keylimepieco You know $VKTX was down X% today right And down over XX% last week 🤣 poor poor cream pie" [X Link](https://x.com/PGainz96934/status/1995623785719074816) 2025-12-01T22:39Z XXX followers, XXX engagements "Big respect to Garg on his way out. People forget hes the one who made the call to bring Pemvidutide into Altimmune. That single decision completely changed the companys trajectory and put $ALT in the middle of the obesity and MASH conversation years before the crowd woke up to it. He did his job. He found the asset backed it and set the table for everything thats coming next. And now hes stepping aside cleanly so Durso whos built for the next phase (regulatory execution partnerships) can take over. No drama just a professional handoff. So congrats to Garg for what he built and props for" [X Link](https://x.com/PGainz96934/status/1995878166850605488) 2025-12-02T15:30Z XXX followers, 1124 engagements "Forcing this Novo will buy Viking narrative but when you actually look at the data and what $NVO really needs it falls apart instantly especially when you stack $VKTX next to $ALT Pemvidutide which is the real prize in this space. Lets be honest: VK2735 is just another me-too dual. Nothing about it is unique. Novo already has multiple internal duals and Lilly is already moving toward triples. Viking doesnt solve anything for them. Pemvi actually does. Pemvidutide brings the one thing Novo is missing: GLP-1 + balanced glucagon not GIP Massive liver-fat and lipid wins Better body-composition" [X Link](https://x.com/PGainz96934/status/1996183526278885819) 2025-12-03T11:43Z XXX followers, 1592 engagements "This take is blatantly false. Novo doesnt need $VKTX to catch Lilly and Viking isnt the key that closes that gap. If theres one asset that actually moves the needle for $NVO its $ALT Pemvidutide. Why Because $VKTX doesnt solve $NVO problems: their dual agonist still has GI tolerability issues high dropout no metabolic breadth and zero MASH clarity. Its a nice-to-have not a strategic necessity. $ALT Pemvi on the other hand is the necessity. Its the only late-stage molecule that: Delivers GLP-1 + GC dual activity without the brutal nausea Shows industry-leading lean-mass preservation a massive" [X Link](https://x.com/PGainz96934/status/1996596169581978037) 2025-12-04T15:03Z XXX followers, XXX engagements "Listened to the Jefferies fireside chat with $ALT yesterday multiple times and came away extremely impressed with the new CEO. Dursos delivery experience and overall demeanor stood out especially his repeated emphasis on shareholder value commercialization strategy and payor-first thinking. Hes clearly operating several steps ahead of the curve. $ALT is now on the cusp of multiple major catalysts: the 48-week biopsy data the FDA end-of-Phase-2 meeting potential oral pemvidutide breakthrough news EMA engagement possible BTD from the FDA and clarity on Phase X structure. A very different tone" [X Link](https://x.com/PGainz96934/status/1996603718020595790) 2025-12-04T15:33Z XXX followers, XXX engagements "This is completely backwards man. Nothing you said about $ALT is actually true and everything you said does describe $VKTX. Lets clear this up: X ALT didnt PR their way ahead of FDA. ALT has literally gone line-by-line with data at AASLD ADA Jefferies Citi and scientific forums. They havent hyped anything; they presented peer-reviewed clinical results that show best-in-class MASH resolution uniquely strong fat reduction and clean safety. Thats called transparency not PR. Meanwhile Viking execs did the exact opposite. $VKTX pumped their market cap into multi-billions off a tiny incomplete" [X Link](https://x.com/PGainz96934/status/1996956263737905658) 2025-12-05T14:54Z XXX followers, XXX engagements "$MDGL went from $XX to over $XXX in nine months once the market finally understood what a true MASH breakthrough looked like. One clean dataset one clear path to approval and the entire valuation reset overnight. Now look at $ALT. Pemvidutide isnt just another MASH drug. Its best-in-class across the metrics that actually matter: Superior fibrosis movement Higher NASH resolution signals Massively better tolerability And it does all this while preserving lean mass; something $MDGL and literally every other drug in development cant touch including $LLY $NVO $VKTX and such $MDGL ran because it" [X Link](https://x.com/PGainz96934/status/1996670440694055348) 2025-12-04T19:58Z XXX followers, 1327 engagements "@Pharmdca Why do only Indian accounts pump $VKTX stock. Can you prove investment in $VKTX Id venture to say you cant but maybe Im wrong" [X Link](https://x.com/PGainz96934/status/1996711630240116750) 2025-12-04T22:42Z XXX followers, 1185 engagements "Important and underappreciated FDA development for $ALT and MASH broadly The FDA has officially qualified AIM-NASH an AI-based histologic tool for use in MASH clinical trials. This standardizes MASH and fibrosis assessment reduces biopsy noise and improves signal detection. For pemvidutide this directly strengthens confidence in the upcoming 48-week biopsy data and materially de-risks Phase X design and regulatory review. Cleaner data lower placebo noise higher PoS. This is exactly the direction FDA has been moving and $ALT is perfectly positioned" [X Link](https://x.com/PGainz96934/status/1998136920141086980) 2025-12-08T21:05Z XXX followers, 4950 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@PGainz96934 Pasha Gainz
Pasha Gainz posts on X about $alt, $vktx, alt, ceo the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +25%
- X Month XXXXXX -XX%
- X Months XXXXXXXXX -XX%
Mentions: X #
- X Week XX -XX%
- X Month XXX +8%
- X Months XXX +864%
Followers: XXX #
- X Week XXX +3.40%
- X Month XXX +17%
- X Months XXX +163%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXX% finance XXXX% technology brands XXXX%
Social topic influence $alt #2, $vktx 13.73%, alt #421, ceo 7.84%, $mdgl 3.92%, $nvo 3.92%, $vik 3.92%, $1020b 1.96%, $gocr 1.96%, events XXXX%
Top accounts mentioned or mentioned by @pharmdca @meadowcapital @keylimepieco @randall21161948 @fat_pockets123 @meangenebio @brwtoovey @xairsman @doctorsalomon @justpavankumar @alt_nicholson @fluffer9 @vtcarguy81 @pacha8x @noureddinmd @aditharun @sanctuarybio @hatedmoats @yaireinhorn @timopler
Top assets mentioned AltLayer (ALT) Viking Therapeutics, Inc (VKTX) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Novo-Nordisk (NVO) Viking Holdings Ltd (VIK) Advanced Micro Devices (AMD) Amgen, Inc. (AMGN) Sanofi (SNY)
Top Social Posts
Top posts by engagements in the last XX hours
"If Evercore is really signaling $1020B takeouts coming in obesity/metabolic theres only one name that actually fits that profile: $ALT Altimmune. Why Because Pemvidutide isnt another GLP-1 copy. Its the only late-stage asset that hits every strategic gap Big Pharma cares about right now: True MASH efficacy + fibrosis improvement Best-in-class lean mass preservation Cleaner tolerability without the brutal nausea curves A GLP-1/GC balance that covers obesity metabolic disease and liver disease in one shot Pipeline in a drug; Obesity MASH AUD ALD and potentially oral Thats not incremental thats"
X Link 2025-12-04T19:47Z XXX followers, 1057 engagements
"Todays move in $GOCR is actually a small but very real catalyst for $ALT. It reinforces how sensitive the market is to any credible oral obesity signal. What matters is the takeaway: convenience and adherence are being rewarded immediately by the market and thats where $ALT could ultimately stand out even more. Pemvidutides profile points to better tolerability and adherence which are the exact pain points holding current orals back. So while $GPCR news isnt about $ALT directly its an obvious sentiment mover. It sets the setup. If and when ALTs oral data or clarity hits the re-rate should be"
X Link 2025-12-08T14:44Z XXX followers, XXX engagements
"Youre absolutely right about patience but the comparison to $MDGL doesnt hold when you look under the hood because $VKTX is dealing with issues Madrigal never had and $ALT Pemvi is the one with the true clean shot at upside. Heres the reality: X Vikings safety & tolerability problems are not normal volatility theyre structural. Madrigal never had: Severe GI events in 44%+ of patients Double-digit discontinuation rates Dose-limiting tolerability even in Phase X But Viking does. That means shrinking eligible patient populations and real commercial limitations. Price volatility is one thing"
X Link 2025-11-25T18:14Z XXX followers, XXX engagements
"@QualityInvest5 Buy $ALT and worry less"
X Link 2025-11-26T21:06Z XXX followers, XXX engagements
"I havent posted in a couple days so heres your Pemvi refresher. While everyone argues about nonsense the only drug in this space that actually checks every box for MASH + obesity is $ALT Pemvidutide (Pemvi). A quick reset: 🚀 Efficacy: Top-tier weight loss without extreme or unsafe dosing Best liver fat reduction outside of a THR drug (competitive even with them) Dramatic CASED improvements and full metabolic cleanup Durability nobody in the incretin crowd has matched 🛡 Safety the real separator: No retatrutide-style GI chaos No $VKTX-style tolerability blowups Discontinuations are"
X Link 2025-11-27T18:26Z XXX followers, XXX engagements
"@Ashton_1nvests $ALT and $AMD"
X Link 2025-11-27T18:27Z XXX followers, XXX engagements
"Not really and heres why. $AMGN Efinopegdutide looks interesting on paper but it still sits in the same class of high-potency incretin stacks that consistently run into the exact problems $ALT Pemvi avoids: GI toxicity scales with potency and efinopegdutides profile already shows the same nausea/vomiting patterns you see with other GLP-1 heavy drugs. Durability is unknown early signals show strong initial drops but no clarity on long-term flattening metabolic stability or real-world tolerability. No liver-first mechanism Pemvi has direct hepatic action (GCGR) that drives MASH improvement in a"
X Link 2025-11-27T19:20Z XXX followers, XXX engagements
"@mvcinvesting Buy $ALT and relax"
X Link 2025-11-27T21:38Z XXX followers, XXX engagements
"@TacticzH EPS will fall off the patent plateau thats why its sold off and will continue to do so unless they make a pipeline changing acquisition such as acquiring $ALT"
X Link 2025-11-28T16:16Z XXX followers, XXX engagements
"🔥 One of the most underrated aspects of $ALT The exec team. Everyone debates data but leadership is another place where Altimmune separates itself from the entire sector. X Vipin Garg PhD CEO Hes the one who acquired pemvidutide early because he saw what others didnt. And he leaned into MASH years before Big Pharma caught on. Vision + conviction. Thats why ALT is ahead of the curve. X Christophe Arbet-Engels MD PhD CMO 30+ years in global pharma running late-stage metabolic/liver programs. Exactly the profile you want entering Phase X MASH. X Linda Richardson CCO Just brought in for"
X Link 2025-11-28T16:36Z XXX followers, 2163 engagements
"Youre lumping drugs together that arent even in the same universe mechanistically or clinically. Already have dual agonists is a perfect example of not understanding the differences between combos vs balance. $ALT Pemvidutide isnt just another dual agonist. Its the ONLY GLP-1/glucagon program with: ✅ Clinically validated high-fat mass loss with industry-best lean preservation Survodutide and Mazdutide both cut lean mass as badly as tirzepatide 2540% of total loss. Pemvi is sitting at XX% lean beating the GLP-1 class and avoiding the glucagon penalty. Thats why HCPs keep calling it the"
X Link 2025-11-29T16:18Z XXX followers, XXX engagements
"Im glad it worked well for you genuinely. But your personal response doesnt erase the clinical reality seen across hundreds of patients. Individual anecdotes population-level safety. 🔹 Retatrutides real safety profile (from the actual data): 4050% of patients experienced moderatesevere GI AEs Discontinuation rates were XX higher than pemvidutide Significant HR and BP elevations CK elevations gallbladder events pancreatitis signals Lipid rebound when dose escalates Lean mass loss 3040% of total weight loss Dose ceilings because tolerability breaks before efficacy does None of that goes away"
X Link 2025-11-29T19:50Z XXX followers, XXX engagements
"@brwtoovey @BowTiedBiotech What you meant to say is that you cant comprehend what Im saying therefore it hurt your head there I fixed it for you smooth brain. Your $VKTX position is in serious trouble no joke"
X Link 2025-11-30T01:51Z XXX followers, XX engagements
"📌 In catalyst-driven names price action is the last thing that matters. For companies like $ALT real value comes from: Strong fundamentals Clinical data and execution A fortified balance sheet Major catalysts ahead (48-week readout FDA EOP2 Phase X design oral Pemvi) Strategic positioning + clear big-pharma interest Thats what rewrites valuations not daily candles. And while people argued over noise the chart quietly started showing accumulation higher lows and a clean uptrend exactly what you see before a catalyst cycle kicks in. This is why you focus on the setup not the swings. When the"
X Link 2025-11-30T02:04Z XXX followers, XXX engagements
"@Mr_Derivatives Yup. Thinking about the millz to be made in $ALT and not even exaggerating"
X Link 2025-11-30T03:39Z XXX followers, XX engagements
"$ALT just made a meaningful leadership shift with Durso stepping in as Garg exits at month-end and the timing is everything. In my opinion this isnt routine; its a strategic repositioning ahead of the most important stretch in the companys lifecycle. With the 48-week MASH biopsy readout approaching the upcoming FDA end-of-Phase-2 meeting and the window for a partnership or strategic transaction bringing in Durso now signals a push for tighter execution stronger communication and clearer alignment. Gargs departure removes a layer investors have questioned recently and gives Durso clean runway"
X Link 2025-12-01T20:34Z XXX followers, XXX engagements
"Durso taking over as CEO is a much bigger signal than people think. This isnt just another management reshuffle in my opinion. This finalizes a leadership realignment that has been quietly building for more than a year. Altimmunes $ALT top leadership now shares an unusually deep commercial and clinical background in metabolic and liver disease and a striking amount of it traces back to Sanofi $SNY. Jerry Durso spent more than XX years at $SNY in senior U.S. and global commercial roles especially in diabetes and metabolic disease before leading Intercept. Linda Richardson the new CCO also came"
X Link 2025-12-01T22:37Z XXX followers, XXX engagements
"@keylimepieco You know $VKTX was down X% today right And down over XX% last week 🤣 poor poor cream pie"
X Link 2025-12-01T22:39Z XXX followers, XXX engagements
"Big respect to Garg on his way out. People forget hes the one who made the call to bring Pemvidutide into Altimmune. That single decision completely changed the companys trajectory and put $ALT in the middle of the obesity and MASH conversation years before the crowd woke up to it. He did his job. He found the asset backed it and set the table for everything thats coming next. And now hes stepping aside cleanly so Durso whos built for the next phase (regulatory execution partnerships) can take over. No drama just a professional handoff. So congrats to Garg for what he built and props for"
X Link 2025-12-02T15:30Z XXX followers, 1124 engagements
"Forcing this Novo will buy Viking narrative but when you actually look at the data and what $NVO really needs it falls apart instantly especially when you stack $VKTX next to $ALT Pemvidutide which is the real prize in this space. Lets be honest: VK2735 is just another me-too dual. Nothing about it is unique. Novo already has multiple internal duals and Lilly is already moving toward triples. Viking doesnt solve anything for them. Pemvi actually does. Pemvidutide brings the one thing Novo is missing: GLP-1 + balanced glucagon not GIP Massive liver-fat and lipid wins Better body-composition"
X Link 2025-12-03T11:43Z XXX followers, 1592 engagements
"This take is blatantly false. Novo doesnt need $VKTX to catch Lilly and Viking isnt the key that closes that gap. If theres one asset that actually moves the needle for $NVO its $ALT Pemvidutide. Why Because $VKTX doesnt solve $NVO problems: their dual agonist still has GI tolerability issues high dropout no metabolic breadth and zero MASH clarity. Its a nice-to-have not a strategic necessity. $ALT Pemvi on the other hand is the necessity. Its the only late-stage molecule that: Delivers GLP-1 + GC dual activity without the brutal nausea Shows industry-leading lean-mass preservation a massive"
X Link 2025-12-04T15:03Z XXX followers, XXX engagements
"Listened to the Jefferies fireside chat with $ALT yesterday multiple times and came away extremely impressed with the new CEO. Dursos delivery experience and overall demeanor stood out especially his repeated emphasis on shareholder value commercialization strategy and payor-first thinking. Hes clearly operating several steps ahead of the curve. $ALT is now on the cusp of multiple major catalysts: the 48-week biopsy data the FDA end-of-Phase-2 meeting potential oral pemvidutide breakthrough news EMA engagement possible BTD from the FDA and clarity on Phase X structure. A very different tone"
X Link 2025-12-04T15:33Z XXX followers, XXX engagements
"This is completely backwards man. Nothing you said about $ALT is actually true and everything you said does describe $VKTX. Lets clear this up: X ALT didnt PR their way ahead of FDA. ALT has literally gone line-by-line with data at AASLD ADA Jefferies Citi and scientific forums. They havent hyped anything; they presented peer-reviewed clinical results that show best-in-class MASH resolution uniquely strong fat reduction and clean safety. Thats called transparency not PR. Meanwhile Viking execs did the exact opposite. $VKTX pumped their market cap into multi-billions off a tiny incomplete"
X Link 2025-12-05T14:54Z XXX followers, XXX engagements
"$MDGL went from $XX to over $XXX in nine months once the market finally understood what a true MASH breakthrough looked like. One clean dataset one clear path to approval and the entire valuation reset overnight. Now look at $ALT. Pemvidutide isnt just another MASH drug. Its best-in-class across the metrics that actually matter: Superior fibrosis movement Higher NASH resolution signals Massively better tolerability And it does all this while preserving lean mass; something $MDGL and literally every other drug in development cant touch including $LLY $NVO $VKTX and such $MDGL ran because it"
X Link 2025-12-04T19:58Z XXX followers, 1327 engagements
"@Pharmdca Why do only Indian accounts pump $VKTX stock. Can you prove investment in $VKTX Id venture to say you cant but maybe Im wrong"
X Link 2025-12-04T22:42Z XXX followers, 1185 engagements
"Important and underappreciated FDA development for $ALT and MASH broadly The FDA has officially qualified AIM-NASH an AI-based histologic tool for use in MASH clinical trials. This standardizes MASH and fibrosis assessment reduces biopsy noise and improves signal detection. For pemvidutide this directly strengthens confidence in the upcoming 48-week biopsy data and materially de-risks Phase X design and regulatory review. Cleaner data lower placebo noise higher PoS. This is exactly the direction FDA has been moving and $ALT is perfectly positioned"
X Link 2025-12-08T21:05Z XXX followers, 4950 engagements